START OF PAGE 1
WES MOORE, Governor Ch. 217

Chapter 217

(House Bill 382)

AN ACT concerning

~~Pharmacy~~ ~~Benefits~~ ~~Administration~~ ~~–~~ ~~Maryland~~ ~~Medical~~ ~~Assistance~~ ~~Program~~ ~~and~~
~~Pharmacy~~ ~~Benefits~~ ~~Managers~~
Maryland Department of Health and Prescription Drug Affordability Board –
Managed Care Organizations and Prescription Drug Claims – Study

FOR the purpose of ~~altering~~ ~~the~~ ~~reimbursement~~ ~~levels~~ ~~for~~ ~~drug~~ ~~products~~ ~~that~~ ~~the~~ ~~Maryland~~
~~Medical~~ ~~Assistance~~ ~~Program~~ ~~is~~ ~~required~~ ~~to~~ ~~establish~~ ~~and~~ ~~that~~ ~~pharmacy~~ ~~benefits~~
~~managers~~ ~~that~~ ~~contract~~ ~~with~~ ~~a~~ ~~pharmacy~~ ~~on~~ ~~behalf~~ ~~of~~ ~~a~~ ~~managed~~ ~~care~~ ~~organization~~
~~are~~ ~~required~~ ~~to~~ ~~reimburse~~ ~~the~~ ~~pharmacy;~~ ~~altering~~ ~~the~~ ~~definition~~ ~~of~~ ~~“purchaser”~~ ~~for~~
~~purposes~~ ~~of~~ ~~certain~~ ~~provisions~~ ~~of~~ ~~law~~ ~~regulating~~ ~~pharmacy~~ ~~benefits~~ ~~managers~~ ~~to~~
~~include~~ ~~certain~~ ~~insurers,~~ ~~nonprofit~~ ~~health~~ ~~services~~ ~~plans,~~ ~~and~~ ~~health~~ ~~maintenance~~
~~organizations~~ requiring the Maryland Department of Health and the Prescription
Drug Affordability Board jointly to study certain information regarding the payment
of prescription drug claims under the Maryland Medical Assistance Program during
certain calendar years and how to address certain inconsistencies; and generally
relating to ~~pharmacy~~ ~~benefits~~ ~~administration~~ managed care organizations and the
payment of prescription drug claims.

~~BY~~ ~~repealing~~ ~~and~~ ~~reenacting,~~ ~~with~~ ~~amendments,~~
~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~
~~Section~~ ~~15–118(b)~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2019~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~

~~BY~~ ~~adding~~ ~~to~~
~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~
~~Section~~ ~~15–118(f)~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2019~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~

~~BY~~ ~~repealing~~ ~~and~~ ~~reenacting,~~ ~~with~~ ~~amendments,~~
~~Article~~ ~~–~~ ~~Insurance~~
~~Section~~ ~~15–1601(s)~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2017~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~

~~BY~~ ~~adding~~ ~~to~~
~~Article~~ ~~–~~ ~~Insurance~~
~~Section~~ ~~15–1632~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2017~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~
– 1 –
END OF PAGE 1

START OF PAGE 2
Ch. 217 2023 LAWS OF MARYLAND

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
That ~~the~~ ~~Laws~~ ~~of~~ ~~Maryland~~ ~~read~~ ~~as~~ ~~follows:~~

~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~

~~15–118.~~

(b) (1) [Except] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION AND
EXCEPT as provided under paragraph [(2)] (3) of this subsection, the Program shall
establish [maximum] reimbursement levels for the drug products for which there is a
generic equivalent authorized under § 12–504 of the Health Occupations Article[, based on
the cost of the generic product].

(2) EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS SUBSECTION,
MINIMUM REIMBURSEMENT LEVELS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
SUBSECTION SHALL BE AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG
ACQUISITION COST OF THE GENERIC PRODUCT PLUS THE
FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETERMINED BY THE
DEPARTMENT IN ACCORDANCE WITH THE MOST RECENT IN–STATE
~~COST–OF–DISPENSING~~ ~~SURVEY.~~

[(2)] (3) [If] EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS
SUBSECTION, IF a prescriber directs a specific brand name drug, the reimbursement level
shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the
brand name product PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE
DETERMINED BY THE DEPARTMENT IN ACCORDANCE WITH THE MOST RECENT
IN–STATE COST–OF–DISPENSING SURVEY.

(4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION DO NOT APPLY TO:

(I) A PHARMACY OWNED BY, OR UNDER THE SAME CORPORATE
AFFILIATION, AS A PHARMACY BENEFITS MANAGER; OR

(II) A MAIL ORDER PHARMACY.

(F) THE PROVISIONS OF § 15–1632 OF THE INSURANCE ARTICLE APPLY TO
~~A~~ ~~MANAGED~~ ~~CARE~~ ~~ORGANIZATION~~ ~~THAT~~ ~~USES~~ ~~A~~ ~~PHARMACY~~ ~~BENEFITS~~ ~~MANAGER~~ ~~TO~~
~~MANAGE~~ ~~PRESCRIPTION~~ ~~DRUG~~ ~~COVERAGE~~ ~~BENEFITS~~ ~~ON~~ ~~BEHALF~~ ~~OF~~ ~~THE~~ ~~MANAGED~~
CARE ORGANIZATION.

~~Article~~ ~~–~~ ~~Insurance~~

~~15–1601.~~

– 2 –
END OF PAGE 2

START OF PAGE 3
WES MOORE, Governor Ch. 217

(s) (1) “Purchaser” means a person that offers a plan or program in the State,
including the State Employee and Retiree Health and Welfare Benefits Program, AN
INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE
ORGANIZATION, that:

[(1)] (I) provides prescription drug coverage or benefits in the State; and

[(2)] (II) enters into an agreement with a pharmacy benefits manager for
~~the~~ ~~provision~~ ~~of~~ ~~pharmacy~~ ~~benefits~~ ~~management~~ ~~services.~~

(2) “PURCHASER” DOES NOT INCLUDE A NONPROFIT HEALTH
MAINTENANCE ORGANIZATION THAT:

(I) OPERATES AS A GROUP MODEL;

(II) PROVIDES SERVICES SOLELY TO A MEMBER OR PATIENT OF
THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION; AND

(III) FURNISHES SERVICES THROUGH THE INTERNAL PHARMACY
OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.

~~15–1632.~~

A PHARMACY BENEFITS MANAGER THAT CONTRACTS WITH A PHARMACY ON
BEHALF OF A MANAGED CARE ORGANIZATION, AS DEFINED IN § 15–101 OF THE
HEALTH – GENERAL ARTICLE, SHALL REIMBURSE THE PHARMACY AN AMOUNT
THAT IS AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST
PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETERMINED BY THE
MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE
PROGRAM IN ACCORDANCE WITH THE MOST RECENT IN–STATE
~~COST–OF–DISPENSING~~ ~~SURVEY.~~

(a) The Maryland Department of Health and the Prescription Drug Affordability
Board jointly shall study:

(1) (i) the total amount the managed care organizations in the State
paid pharmacies for prescription drug claims in calendar years 2021 and 2022; and

(ii) what the total amount paid to pharmacies would have been, in
calendar years 2021 and 2022, if the prescription drug claims had been reimbursed at the
Maryland Medical Assistance Program fee–for–service rates; and

(2) how to best address the inconsistency in the amounts studied under
item (1) of this subsection by:
– 3 –
END OF PAGE 3

START OF PAGE 4
Ch. 217 2023 LAWS OF MARYLAND

(i) considering the total cost to the State; and

(ii) recommending a methodology for determining the most accurate
ingredient cost of a drug and an appropriate dispensing fee.

(b) On or before October 31, 2023, the Maryland Department of Health and the
Prescription Drug Affordability Board jointly shall report its findings to the Maryland
Medicaid Administration and, in accordance with § 2–1257 of the State Government
Article, the Senate Budget and Taxation Committee, the Senate Finance Committee, the
House Appropriations Committee, and the House Health and Government Operations
Committee.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency
measure, is necessary for the immediate preservation of the public health or safety, has
been passed by a yea and nay vote supported by three–fifths of all the members elected to
each of the two Houses of the General Assembly, and shall take effect from the date it is
enacted.

Approved by the Governor, April 24, 2023.

– 4 –
END OF PAGE 4